Cargando…

The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease

A longitudinal molecular model of the development and progression of nonalcoholic fatty liver disease (NAFLD) over time is lacking. We have recently validated a high fat/sugar water-induced animal (an isogenic strain of C57BL/6 J:129S1/SvImJ mice) model of NAFLD that closely mimics most aspects of h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cazanave, Sophie, Podtelezhnikov, Alexei, Jensen, Kristian, Seneshaw, Mulugeta, Kumar, Divya P., Min, Hae-Ki, Santhekadur, Prasanna K., Banini, Bubu, Mauro, Adolfo Gabriele, M. Oseini, Abdul, Vincent, Robert, Tanis, Keith Q., Webber, Andrea L., Wang, Liangsu, Bedossa, Pierre, Mirshahi, Faridoddin, Sanyal, Arun J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722878/ https://www.ncbi.nlm.nih.gov/pubmed/29222421 http://dx.doi.org/10.1038/s41598-017-17370-6

Ejemplares similares

Author Correction: The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
por: Cazanave, Sophie, et al.
Publicado: (2020)

A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer
por: Asgharpour, Amon, et al.
Publicado: (2016)

Second-Harmonic Generated Quantifiable Fibrosis Parameters Provide Signatures for Disease Progression and Regression in Nonalcoholic Fatty Liver Disease
por: Ng, Nicole, et al.
Publicado: (2023)

Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease
por: Pacana, Tommy, et al.
Publicado: (2015)

Editorial: Recent advances in the understanding of hepatocellular carcinogenesis
por: Banini, Bubu A., et al.
Publicado: (2022)

Withaferin A Acts as a Novel Regulator of Liver X Receptor-α in HCC
por: Shiragannavar, Varsha D., et al.
Publicado: (2021)

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
por: Kumar, Divya P., et al.
Publicado: (2020)

The use of cell free DNA in the diagnosis of HCC
por: Banini, Bubu A., et al.
Publicado: (2019)

Gene Expression Predicts Histological Severity and Reveals Distinct Molecular Profiles of Nonalcoholic Fatty Liver Disease
por: Hoang, Stephen A., et al.
Publicado: (2019)

An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis
por: Luo, Yi, et al.
Publicado: (2018)

The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review
por: Chen, George, et al.
Publicado: (2023)

The crosstalking immune cells network creates a collective function beyond the function of each cellular constituent during the progression of hepatocellular carcinoma
por: Koelsch, Nicholas, et al.
Publicado: (2023)

Molecular Insights into the Pathogenesis of Alzheimer's Disease and Its Relationship to Normal Aging
por: Podtelezhnikov, Alexei A., et al.
Publicado: (2011)

Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
por: Chen, George, et al.
Publicado: (2023)

RISC assembly and post-transcriptional gene regulation in Hepatocellular Carcinoma
por: Santhekadur, Prasanna K., et al.
Publicado: (2019)

Editorial: Congruities between cancer and infectious diseases: Lessons to be learned from these distinct yet analogous fields
por: Thirunavukkarasu, Shyamala, et al.
Publicado: (2022)

New uses for an old remedy: Digoxin as a potential treatment for steatohepatitis and other disorders
por: Jamshed, Fatima, et al.
Publicado: (2023)

Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development
por: Kriss, Michael, et al.
Publicado: (2020)

Restoration of CD4(+) T Cells during NAFLD without Modulation of the Hepatic Immunological Pattern Is Not Sufficient to Prevent HCC
por: Isbell, Madison, et al.
Publicado: (2022)

The dark face of fructose as a tumor promoter
por: Santhekadur, Prasanna K.
Publicado: (2019)

Development of Alcohol‐Associated Hepatitis Is Associated With Specific Changes in Gut‐Modified Bile Acids
por: Muthiah, Mark D., et al.
Publicado: (2022)

Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review
por: Cariou, Bertrand, et al.
Publicado: (2021)

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
por: Estes, Chris, et al.
Publicado: (2017)

The transcontinental variability of nonalcoholic fatty liver disease
por: Oliveira, Claudia P., et al.
Publicado: (2020)

Extracellular Vesicles as Inflammatory Drivers in NAFLD
por: Srinivas, Akshatha N., et al.
Publicado: (2021)

CRANKITE: A fast polypeptide backbone conformation sampler
por: Podtelezhnikov, Alexei A, et al.
Publicado: (2008)

Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD
por: Smirnova, Ekaterina, et al.
Publicado: (2022)

Herbal Immunity Booster-Associated Liver Injury During COVID-19 Pandemic and Aflatoxins
por: Vamadevaiah, Ravishankar M., et al.
Publicado: (2022)

COVID-19 and gastrointestinal system: A brief review
por: Pola, Akhil, et al.
Publicado: (2021)

Editorial: Chemotherapy in esophageal cancer
por: Chen, Jiang, et al.
Publicado: (2022)

Nonalcoholic fatty liver disease is specifically related to the risk of hepatocellular cancer but not extrahepatic malignancies
por: Albhaisi, Somaya, et al.
Publicado: (2022)

Distinct hepatic immunological patterns are associated with the progression or inhibition of hepatocellular carcinoma
por: Mirshahi, Faridoddin, et al.
Publicado: (2022)

The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator
por: Shiragannavar, Varsha D., et al.
Publicado: (2023)

Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
por: Kleiner, David E., et al.
Publicado: (2019)

Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis
por: Albhaisi, Somaya, et al.
Publicado: (2021)

Drug discovery and treatment paradigms in nonalcoholic steatohepatitis
por: Noureddin, Mazen, et al.
Publicado: (2019)

Comparative transcriptomics of choroid plexus in Alzheimer’s disease, frontotemporal dementia and Huntington’s disease: implications for CSF homeostasis
por: Stopa, Edward G., et al.
Publicado: (2018)

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
por: Siddiqui, Mohammad Shadab, et al.
Publicado: (2018)

Multi-SNP Analysis of GWAS Data Identifies Pathways Associated with Nonalcoholic Fatty Liver Disease
por: Chen, Qing-Rong, et al.
Publicado: (2013)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_c244r6sp8qfhqqf2ar6bfrt613